Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
YUAN LU
CONTACT
Siqing Fu, MD
CONTACT
Lead
Abbisko Therapeutics Co, Ltd
The study will start with a dose escalation part of single-agent ABSK021 administered in repeated 28-day cycles in patients with advanced solid for safety and tolerability. The expansion part of oral ABSK021 at recommended dose of expansion (RDE) will be followed for further evaluating safety and tolerability among selected tumor types. Preliminary antitumor activity will also be assessed.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted